Innoviva (INVA) Competitors

Alkermes (NASDAQ:ALKS) and Innoviva (NASDAQ:INVA) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, media sentiment, analyst recommendations, profitability, risk and dividends.

Do analysts rate ALKS or INVA?

Alkermes currently has a consensus target price of $41.08, indicating a potential upside of 38.10%. Innoviva has a consensus target price of $42.75, indicating a potential upside of 112.05%. Given Innoviva's stronger consensus rating and higher possible upside, analysts plainly believe Innoviva is more favorable than Alkermes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alkermes	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.83
Innoviva	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00

Do institutionals and insiders have more ownership in ALKS or INVA?

95.2% of Alkermes shares are owned by institutional investors. Comparatively, 99.1% of Innoviva shares are owned by institutional investors. 4.4% of Alkermes shares are owned by insiders. Comparatively, 2.3% of Innoviva shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Which has more volatility & risk, ALKS or INVA?

Alkermes has a beta of 0.47, meaning that its stock price is 53% less volatile than the S&P 500. Comparatively, Innoviva has a beta of 0.38, meaning that its stock price is 62% less volatile than the S&P 500.

Which has stronger valuation and earnings, ALKS or INVA?

Alkermes has higher revenue and earnings than Innoviva. Alkermes is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alkermes	$1.56B	3.15	$367.07M	$2.08	14.30
Innoviva	$370.23M	3.43	$23.39M	$0.31	65.03

Is ALKS or INVA more profitable?

Alkermes has a net margin of 23.15% compared to Innoviva's net margin of 10.44%. Alkermes' return on equity of 24.86% beat Innoviva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alkermes	23.15%	24.86%	17.14%
Innoviva	10.44%	18.67%	9.92%

Does the media refer more to ALKS or INVA?

In the previous week, Alkermes had 16 more articles in the media than Innoviva. MarketBeat recorded 23 mentions for Alkermes and 7 mentions for Innoviva. Innoviva's average media sentiment score of 1.19 beat Alkermes' score of 0.75 indicating that Innoviva is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alkermes	10 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Innoviva	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Alkermes beats Innoviva on 11 of the 17 factors compared between the two stocks.